SLC25A5-AS1: A Potential Drug Target and Biomarker (G100303728)

Target Name: SLC25A5-AS1

NCBI ID: G100303728

SLC25A5-AS1

Other Name(s): SLC25A5 antisense RNA 1 | SLC25A5-AS1 variant 1 | SLC25A5 antisense RNA 1, transcript variant 1

SLC25A5-AS1: A Potential Drug Target and Biomarker

Sodium-dependent lactose transporter 2 (SLC25A5) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, diabetes, and neurological disorders. SLC25A5 is a member of the SLC gene family, which is known for its role in transporting various types of molecules across cell membranes. The SLC25A5 gene has been shown to be expressed in a variety of tissues and organs, including the brain, pancreas, liver, and muscle.

SLC25A5 has been shown to play a role in the regulation of various physiological processes in the body, including the absorption of nutrients, such as lactose, into the bloodstream. In addition, SLC25A5 has been shown to be involved in the regulation of ion and water transport, as well as the production of certain signaling molecules that are involved in cellular processes.

SLC25A5 has also been shown to be involved in the development and progression of certain diseases, including cancer. For example, studies have shown that high levels of SLC25A5 are associated with poor prognosis in patients with pancreatic cancer, and that inhibition of SLC25A5 has been shown to improve survival in these patients.

In addition to its potential as a drug target, SLC25A5 has also been shown to be a potential biomarker for certain diseases. For example, studies have shown that SLC25A5 is expressed in the brains of patients with Alzheimer's disease, and that decreased levels of SLC25A5 have been associated with increased risk of developing this disease. Additionally, SLC25A5 has been shown to be involved in the regulation of neurotransmitter release in the brain, which may be relevant to the development of certain neurological disorders.

In conclusion, SLC25A5 is a gene that has been identified as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand the role of SLC25A5 in these processes and to develop safe and effective treatments for these diseases.

Protein Name: SLC25A5 Antisense RNA 1

The "SLC25A5-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A5-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets